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entacaponeAbstract To assess the signal of death associated with the use of an entacapone-containing drug
combination in the FDA Adverse Event Reporting System (FAERS) database.
Reports of death events submitted between January 2004 and December 2010 were retrieved and
analysed by the reporting odds ratio (ROR). The ROR of case/non-case reports of death associated
with an entacapone-containing drug combination was compared with the levodopa/carbidopa
combination using the FDA AERS database.
Eighty-seven reports linked the entacapone-containing drug combination to death, compared to
27 reports of death linking the levodopa/carbidopa combination. The ROR was statistically signif-
icant for the association between deaths with the use of an entacapone-containing drug combina-
tion (1.86 [95% CI 1.50–2.31]). In contrast, the ROR of death associated with the combination
of levodopa and carbidopa was not statistically signiﬁcant (0.89 [95% CI 0.61–1.30)].
Based on analysing reports in the FAERS database, there is a risk of death with the use of an
entacapone-containing drug combination. These results generated a signal of death with the use
of this drug. However, epidemiological studies are required to conﬁrm this association.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Entacapone is a catecholamine-o-methyl transferase (COMT)
inhibitor. The drug was approved in October 1999 as a single
ingredient (marketed as Comtan) and in June 2003 as a com-
bination pill containing levodopa, carbidopa and entacapone
(marketed as Stalevo). It is indicated as an adjunct to levo-
dopa/carbidopa therapy in patients with Parkinson’s disease
(PD) who experience the signs and symptoms of end-of-dose
‘‘wearing-off’’. It has been found that up to 50% of patients
Use of an entacapone-containing drug combination and risk of death 29develop motor complications and end-of-dose ‘‘wearing-off’’
after 5 years of treatment with levodopa (Standaert and
Young, 2001). COMT inhibitors are added to levodopa treat-
ment to overcome these complications and to prolong the bio-
availability of levodopa (Rivest et al., 1999).
In recent years, concerns have been raised about the safety
of COMT inhibitors. Tolcapone was the ﬁrst COMT inhibitor
to be approved, but it was withdrawn in the European Union
and in other countries after rare reports of death due to hepatic
toxicity (World Health Organisation, 2001; Olanow and
Watkins, 2007). On the other hand, entacapone was consid-
ered to be safe and well-tolerated with regard to hepatotoxicity
(Brooks, 2004).
However, recent ﬁndings from the Stalevo Reduction in
Dyskinesia Evaluation-Parkinson Disease (STRIDE-PD)
study have raised concerns over the safety of entacapone
(Brooks, 2004; Stocchi et al., 2010). The STRIDE-PD study
compared levodopa/carbidopa with or without entacapone in
747 patients with PD. The trial reported an imbalance in some
serious outcomes, including the incidence of prostate cancer
and myocardial infarction in patients treated with levodopa,
carbidopa and entacapone compared to those receiving only
levodopa/carbidopa (Stocchi et al., 2010; Food and Drug
Administration, 2010a).
On March 31 2010, the US Food and Drug Administration
(FDA) announced that they were evaluating data from the
STRIDE-PD clinical trial which suggested that patients taking
Stalevo may be at an increased risk of developing prostate
cancer (Food and Drug Administration, 2010a). The FDA
has not yet concluded that Stalevo increases the risk of devel-
oping prostate cancer. Moreover, on August 20, 2010, the
FDA conducted a meta-analysis that included 15 clinical trials
based on the ﬁndings from the STRIDE-PD trial. A small
increased risk of cardiovascular adverse events was found in
the Stalevo group.(Food and Drug Administration, 2010b).
The purpose of this study was to assess the signal of death
associated with the use of an entacapone-containing drug com-
bination based on the cases of death submitted to the FDA
Adverse Events Reporting System (FAERS) database.
2. Methods
The FDA adverse event reporting system (FAERS) was uti-
lised to assess the association between the use of an entaca-
pone-containing drug combination and the signal of death
using a case/non-case method. All reports that were available
in the FDA AERS database from January 2004 to December
2010 were accessed and downloaded from the FDA website
(http://www.fda.gov/). However, in the dataset from 2004,
there were some reports dated before 2004. FAERS is a spon-
taneous reporting system that contains data on adverse drug
events and medication errors submitted to the FDA (Food
and Drug Administration, 0000).
The FDA AERS contains either all or some of the informa-
tion on the MedWatch reporting form that is usually sent by
healthcare professionals as well as patients or consumers from
the United States (U.S.) or outside the U.S. In addition, this
system includes reports sent from the manufacturers for seri-
ous adverse drug reactions in the U.S. or serious and unla-
belled spontaneous reports from outside the U.S. It is worth
noting that any report should include four elements to beconsidered a valid report prior to entry into the system: an
identiﬁable patient, an identiﬁable reporter, the suspected drug
and the adverse drug event. The reporter and suspected drug
elements are available as free text while the adverse drug events
are coded by the Medical Dictionary for Regulatory Activities
(MedDRA). The MedDRA term level used to code the adverse
drug event is the preferred term (PT) Food and Drug
Administration, 0000; Poluzzi et al., 2009, 2010.
The main group of medications of interest was drugs that
include entacapone for the treatment of Parkinson’s disease.
Stalevo is the only drug that contains entacapone (Food
and Drug Administration, 2010a). Another group of medica-
tions was also included in this study, i.e. the combination of
levodopa and carbidopa, which is marketed as Sinemet. Ent-
acapone is either used as a separate pill with levodopa and car-
bidopa or as a combination of the three drugs in one pill, as in
the case of Stalevo (Food and Drug Administration, 2010a).
Both the trade and generic (chemical name) names were used
to extract the reports that included entacapone-containing
products as well as other drugs included in this study. The out-
come of interest was death, and was searched using the term
‘‘death’’ in the PT ﬁeld in the FAERS database.
A case/non-case method was used to analyse the associa-
tion between the use of drugs of interest and the signal of
death. Cases were the reports of the outcome of interest, which
was ‘‘death’’, and were extracted using the PT for any given
drug, while the non-cases were all other reports related to
the same drug (other than the reports of the outcome of inter-
est, which was death). All death terms that were not related to
the population of the study, for example ‘‘neonatal death’’ and
‘‘inter-uterine death’’, were excluded. For both cases and non-
cases, only reports that considered the drug of interest as the
primary suspected drug were included in the analysis. The
reporting odds ratio (ROR), as a measure of disproportional-
ity, was used to assess the association between the drug of
interest and death. The ratio of case/non-case reports for each
group (the entacapone-containing drug combination group
and the levodopa/carbidopa group) were compared to other
medications. The ROR calculation is explained in detail else-
where (Moore et al., 1997). All statistical analyses were per-
formed using SAS software (version 9.2) (SAS Institute
Inc., Cary, North Carolina, USA).
3. Results
From the period between January 2004 and December 2010,
there were 5062 reports that included entacapone; of these
reports, there were 2532 reports in which the drug was consid-
ered the primary suspected cause of the outcome of interest (all
outcomes). Of these reports, there were 87 reports that linked
the entacapone-containing drug combination to be the primary
suspected cause of death. For medications including levodopa
and carbidopa only, out of 9477 reports, there were 1670
reports that considered the drug to be the primary suspected
cause of the outcome of interest. Of these reports, there were
27 reports that linked the levodopa and carbidopa combina-
tion to the primary suspected cause of death.
The ROR of death associated with the entacapone-contain-
ing drug combination was statistically signiﬁcant (1.86 [95%
CI 1.50–2.31]). Conversely, the ROR of death associated with
the combination of levodopa and carbidopa was not
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Age was recorded in 48 cases of those who were using the ent-
acapone-containing drug combination; the mean age was
75 years with a minimum age of 50 years and a maximum
age of 93 years. Only seven cases of patients who were using
the combination of levodopa and carbidopa contained the
age information; the mean age was 72, the minimum age was
40 years and the maximum age was 87 years. The majority of
cases in both groups were males (entacapone group 64% and
levodopa/carbidopa group 73%).
A stratiﬁed year-by-year analysis was performed for events
of death occurred in levodopa/carbidopa/entacapone group
and levodopa/carbidopa group (Fig. 1). We noticed that the
peak of cases for the entacapone group was in 2009 and
2010, while the peak of cases for levodopa and carbidopa
was in 2006 and 2007. Five cases in the entacapone group
occurred in clinical studies.
In the entacapone-containing drug combination group,
although all cases had information on the primary suspected
drug, some cases had information on concomitant drug use.
As concomitant medications, other anti-Parkinson’s disease
drugs (e.g. pergolide and pramipexole), hypotensive agents
(e.g. angiotensin converting enzyme inhibitors) andTable 1 ROR of death for the levodopa/carbidopa/entacapone and
Active substances Death events
Levodopa/carbidopa/entacapone 87
Levodopa/carbidopa 27
ADR: adverse drug reaction, ROR: reporting odds ratio, 95% CI: 95%
Figure 1 Number of events of death in levodopa/carbidopa/entacantidepressants (e.g. selective sertonin reuptake inhibitors)
were the concomitant medications in the entacapone-contain-
ing drug combination group. In contrast, few patients had
information on concomitant drug use in the levodopa/carbi-
dopa group. Examples of these drugs include anti-Parkinson’s
disease drugs (e.g. pramipexole), lipid lowering agents (e.g.
statins) and antidepressant agents (selective sertonin reuptake
inhibitors).4. Discussions
The Food and Drug Administration Adverse Event Reporting
System (FAERS) is one of the largest databases (it has over
four million reports at the current time) and is considered to
be a source for data mining and signal detection in addition
to the World Health Organisation database (VigiBase) that
includes more than seven million reports (Poluzzi et al.,
2009; Food and Drug Administration, 0000; World Health
Organisation, 0000). However, the FAERS database can be
freely accessed without charge to allow researchers to investi-
gate any signal from these reports (Poluzzi et al., 2009). The
FAERS database is a very useful and important tool forlevodopa/carbidopa drug combinations.




apone group and levodopa/carbidopa group stratiﬁed by year.
Use of an entacapone-containing drug combination and risk of death 31post-marketing surveillance and for pharmacovigilance and
drug safety activities, especially for serious events (Hochberg
et al., 2007).
In this study, we used a case/non-case method, which has
been utilised by many studies (Poluzzi et al., 2009; Piccinni
et al., 2011; Motola et al., 2012). This method has been
explained in detail elsewhere (Moore et al., 1997). Our study
found an association between the use of the entacapone-con-
taining drug combination and death. While this association
was not seen in patients using the levodopa/carbidopa combi-
nation, the risk would be the same since there is only one extra
substance in Stalevo (levodopa, carbidopa and entacapone)
compared to Sinemet (levodopa and carbidopa). However,
Stalevo (levodopa/carbidopa/entacapone) has several safety
concerns, especially following the STRIDE-PD study. In
March 2010, the FDA published a safety communication on
the risk of prostate cancer with Stalevo use. The FDA was
evaluating the STRIDE-PD study because this study raised
concerns over the safety of entacapone. The STRIDE-PD
study compared levodopa/carbidopa with or without entaca-
pone in 747 patients with PD (Stocchi et al., 2010). The trial
reported an imbalance in some serious outcomes, including
the incidence of prostate cancer in patients treated with levo-
dopa, carbidopa and entacapone compared to those receiving
only levodopa/carbidopa. There were nine cases of prostate
cancer in the 245 participants (3.7%) in the Stalevo group,
while there were two cases out of 222 participants (0.9%) in
the levodopa/carbidopa group. The incidence of prostate can-
cer was 14 per 1000 patient years for the Stalevo group and
3.2 per 1000 patient years for the levodopa/carbidopa group
(Stocchi et al., 2010; Food and Drug Administration, 2010a).
However, other trials before the STRIDE-PD study did not
raise any safety concerns as this trial. Yet, most of these trials
were conducted over a short period of time (less than a year)
compared to the STRIDE-PD study, which was conducted
for over 4 years (Food and Drug Administration, 2010a).
Furthermore, on August 2010, the FDA also announced a
safety communication mentioning that there is an increased
risk of cardiovascular events, such as heart attack, stroke
and cardiovascular death with the use of Stalevo compared
to patients using levodopa/carbidopa based on data from a
clinical trial. The risk of cardiovascular events was ﬁrst found
in the STRIDE-PD study, as there were seven cases of myocar-
dial infarction and one case of cardiovascular death in the Sta-
levo group while there were zero cases of both myocardial
infarction and cardiovascular death in the levodopa/carbidopa
group. Moreover, the FDA performed a meta-analysis to
investigate this risk. This meta-analysis included data from
15 clinical trials. Twenty-seven cardiovascular events occurred
in the Stalevo group and 10 events occurred in the levodopa/
carbidopa group; the relative risk was 2.46, 95% CI 1.19, and
5.09. However, the method of performing this meta-analysis
has several limitations (Food and Drug Administration,
2010b). Cardiovascular death was one of the endpoints inves-
tigated in both the STRIDE-PD study and the meta-analysis
performed by the FDA. Therefore, we used death (all causes
of death) as our endpoint in this study. The results of our study
are similar to the results of the meta-analysis performed by the
FDA and consistent with the results of the STRIDE-PD trial
with respect to the occurrence of death (Food and Drug
Administration, 2010b).Parkinson’s disease is not a fatal disease and is not associ-
ated with high mortality. However, the risk increased in
patients who developed dementia (de Lau et al., 2005). There-
fore, we believe that the risk of death associated with patients
in the levodopa/carbidopa/entacapone group is not related to
the disease itself, because the risk only occurred in the levo-
dopa/carbidopa/entacapone group while it did not occur in
the levodopa/carbidopa group, despite the fact that both
groups had the same disease. Concomitant medications were
used as a proxy for concomitant disease to assess the risk fac-
tors for those patients. Most of these drugs were used for com-
mon diseases that affect this age group, such as hypertension
and hyperlipidaemia. Furthermore, some of the patients in
both groups had depression. It does not seem that these risk
factors had a major effect on the study outcome. Although
antidepressant use is associated with the risk of suicide, this
does not seem important here because (1) both groups were
using antidepressants and (2) the risk of death was higher only
in patients in the levodopa/carbidopa/entacapone group.
Notoriety bias occurs when the number of reports increases
following safety alerts, especially those from regulatory bodies
(Tuccori et al., 2010). Although notoriety bias could have had
an effect on the results of our study, we do not believe that the
association between Stalevo and death can be explained only
by notoriety bias. We noted that there was an increasing trend
in the risk of death from 2004 to 2009. Furthermore, the num-
ber of cases of death in 2010 was less than in 2009 in the ent-
acapone group. The demographics of the cases of death in our
study were consistent with the epidemiology of Parkinson’s
disease. The mean age was more than 60 years and the risk
was more in males than females (de Lau and Breteler, 2006).
To our knowledge, the present study is the ﬁrst study to use
the FAERS database to investigate the signal of death with
Stalevo and levodopa/carbidopa.
As mentioned previously, this study has several advantages
such as using rich open access data to assess medication safety
signals. This database includes millions of reports and covers
the entire American population and also contains reports from
other countries. This advantage is important to investigate rare
events. This advantage allows for an independent external
researcher to evaluate these medications and is not limited to
investigations by US FDA staff. Also, this is the ﬁrst study
to use the FAERS database to assess the risk of death with
the use of commonly used anti-Parkinson’s medications.
However, this study has several limitations, especially with
respect to the case/non-case method and any spontaneous
reporting system, i.e. (1) under-reporting bias, (2) over-report-
ing bias which happens due to recent safety alerts and the
notoriety bias, (3) missing of data or lack of information, espe-
cially regarding patient lifestyle information or occupational
risks, (4) the Weber effect, which is an increase in the number
of reports following the approval of new drugs (Hartnell et al.,
2003) and (5) the inability to assess the drug-event causal rela-
tionship. These limitations are common with all studies that
use spontaneous reporting systems and ROR analysis.
5. Conclusion
The results of our study found an association between the use
of the entacapone-containing drug combination and death;
32 T.M. Alshammari, E.N. AlMutairithis association was not seen in patients using the levodopa/
carbidopa combination.
Despite the limitations of the case/non-case method and the
FDA AERS database, we believe that the data in this study
may offer an important reference for deﬁning the safety proﬁle
of entacapone. Further epidemiological studies (case control
or cohort studies) should be utilised to investigate the safety
of this medication.
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